

Padcev[™] (enfortumab vedotin-ejfv) – New drug approval

- On December 18, 2019, the <u>FDA announced</u> the approval of <u>Seattle Genetics</u>' and <u>Astellas Pharma's Padcev (enfortumab vedotin-ejfv)</u>, for the treatment of adult patients with locally advanced or metastatic urothelial cancer who have previously received a programmed death receptor-1 (PD-1) or programmed death-ligand 1 (PD-L1) inhibitor, and a platinum-containing chemotherapy in the neoadjuvant/adjuvant, locally advanced or metastatic setting.
 - This indication is approved under accelerated approval based on tumor response rate.
 Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trials.
- Bladder cancer is the sixth most common cancer in the U.S. and urothelial cancer accounts for more than 90% of cases. Urothelial cancer begins in cells that line the bladder and nearby organs. Platinumcontaining chemotherapy, PD-1 and PD-L1 inhibitors are standard treatments for patients with bladder cancer.
- Padcev is a first-in-class antibody-drug conjugate that is directed against Nectin-4, a protein located on the surface of cells and highly expressed in bladder cancer.
 - Nonclinical data suggest the anticancer activity of Padcev is due to its binding to Nectin-4
 expressing cells followed by the internalization and release of the anti-tumor agent
 monomethyl auristatin E into the cell, which results in the cell not reproducing (cell cycle
 arrest) and in programmed cell death (apoptosis).
- The efficacy of Padcev was established in EV-201, a single-arm study in 125 patients with locally advanced or metastatic urothelial cancer who received prior treatment with a PD-1 or PD-L1 inhibitor and platinum-based chemotherapy. The major efficacy outcome measures were confirmed objective response rate (ORR) and duration of response (DOR).
 - The confirmed ORR was 44% (95% CI: 35.1, 53.2).
 - The median DOR was 7.6 months (95% CI: 6.3, not estimable).
- Warnings and precautions for Padcev include hyperglycemia, peripheral neuropathy, ocular disorders, skin reactions, infusion site extravasation, and embryo-fetal toxicity.
- The most common adverse reactions (≥ 20%) with Padcev use were fatigue, peripheral neuropathy, decreased appetite, rash, alopecia, nausea, dysgeusia, diarrhea, dry eye, pruritus, and dry skin.
- The recommended dose of Padcev is 1.25 mg/kg (up to a maximum of 125 mg for patients ≥ 100 kg) administered as an intravenous infusion over 30 minutes on Days 1, 8 and 15 of a 28-day cycle until disease progression or unacceptable toxicity.
- Seattle Genetics' and Astellas Pharma's launch plans for Padcev are pending. Padcev will be available as a 20 mg and 30 mg lyophilized powder in single-dose vials.



OptumRx[®] specializes in the delivery, clinical management and affordability of prescription medications and consumer health products. We are an Optum[®] company — a leading provider of integrated health services. Learn more at **optum.com**.

All Optum® trademarks and logos are owned by Optum, Inc. All other brand or product names are trademarks or registered marks of their respective owners.

This document contains information that is considered proprietary to OptumRx and should not be reproduced without the express written consent of OptumRx.

RxNews® is published by the OptumRx Clinical Services Department.

©2019 Optum, Inc. All rights reserved.